CT
CTOR.US Citius Oncology, Inc.
- Market cap
- USD 60.7M
- P/E
- -
- P/B
- 1.37x
- ROE
- -135.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is CTOR.US undervalued?
Graham numberThe Graham number of Citius Oncology, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Citius Oncology, Inc. fundamental analysis
No fundamental analysis for Citius Oncology, Inc. yet.
Citius Oncology, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Full company profileCitius Oncology, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Citius Oncology, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 9.47M |
| Gross Profit | - | - | - | - | - | 5.03M |
| Operating Income | - | -9.71M | -12.1M | -20.6M | -23.5M | -56.8M |
| EBITDA | -10.1K | -4.86M | -12.1M | -20.6M | -23.5M | -51.3M |
| Net Income | -10.1K | -10.9M | -12.7M | -21.1M | -24.8M | -54.8M |
| EPS | 0.00 | -0.12 | -0.14 | -0.30 | -0.34 | -0.51 |
| Balance Sheet | ||||||
| Total Assets | - | 42.7M | 47.7M | 84.4M | 101M | 112M |
| Total Liabilities | - | 6.42M | 22.2M | 38.2M | 56.1M | 71.7M |
| Shareholders' Equity | - | 36.3M | 25.5M | 46.1M | 44.9M | 40.4M |
| Cash & Short-term Investments | - | 289K | 26.5K | 112.00 | 3.92M | 16.6M |
| Total Debt | - | - | - | 3.80M | 3.80M | 10.2M |
| Cash Flow | ||||||
| Operating Cash Flow | - | -48.0K | -601K | 126K | -5.49M | -18.9M |
| Capital Expenditure | - | 0.00 | 4.00 | 4.00 | 4.00 | 2.67M |
| Free Cash Flow | - | -48.0K | -601K | 126K | -5.49M | -18.9M |
| Ratios | ||||||
| ROE | - | -30.0% | -49.7% | -45.8% | -55.2% | -135.6% |
| ROA | - | -25.5% | -26.6% | -25.1% | -24.5% | -48.8% |
| Net Profit Margin | - | - | - | - | - | -578.0% |
| Debt to Equity | - | - | - | 0.08x | 0.08x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Citius Oncology, Inc. dividends
Citius Oncology, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Citius Oncology, Inc.
- Insiders 77.51%
- Institutions 14.97%
- Public & others 7.52%
- Shares outstanding 106M
- Free float 31.0M
Top funds holding CTOR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 370K | 0.35% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 134K | 0.13% | +37.02% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 54.7K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 26.3K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 23.4K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding CTOR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.71M | 8.23% | -5.26% | Jun 2026 |
| Bank of America Corp | 3.84M | 3.63% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 546K | 0.52% | +2.15% | Jun 2026 |
| UBS Group AG | 335K | 0.32% | +808.30% | Jun 2026 |
| Geode Capital Management, LLC | 245K | 0.23% | -7.30% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 122K | 0.12% | 0.00% | Jun 2026 |
| IFP Advisors, LLC | 107K | 0.10% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 90.6K | 0.09% | 0.00% | Jun 2026 |
| Northern Trust Corp | 45.7K | 0.04% | 0.00% | Jun 2026 |
| State Street Corp | 42.9K | 0.04% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 21.9K | 0.02% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 20.6K | 0.02% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 13.8K | 0.01% | 0.00% | Jun 2026 |
| Arkadios Wealth Advisors | 11.7K | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.00K | 0.00% | -90.12% | Jun 2026 |
| Wells Fargo & Co | 500.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 200.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 90.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 23.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
Citius Oncology, Inc. company profile
- Company name
- Citius Oncology, Inc.
- Ticker
- CTOR.US
- Exchange
- USA Stocks
- Listed since
- Dec 8, 2022
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- September
- Address
- 11 Commerce Drive, Cranford, NJ, United States, 07016
- Phone
- 908 967 6677
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Citius Oncology, Inc. management
4- Mr. Leonard L. MazurCEO, President & Executive Chairman · born 1945
- Mr. Myron Z. HolubiakSecretary & Executive Vice Chairman · born 1947
- Dr. Myron S. Czuczman M.D.Executive VP & Chief Medical Officer · born 1960
- Mr. Jaime BartushakCFO & Treasurer · born 1968